| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Esperion Therapeutics, Inc. (ESPR) has 9 insiders with recent SEC Form 4 filings, including 6 buys and 16 sells. ESPR is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.47M | $4.65M | - | |
| CFO | 467.5K | $1.48M | - | |
| Other | 385.9K | $1.22M | - | |
| Other | 380.0K | $1.20M | - | |
| Dir | 177.5K | $561.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jul 6, 2016 | McGovern Mark E | Director | Buy | 5,000 | $10.00 | $50,000.00 | +833.3% | |
| May 4, 2016 | Mayleben Timothy M | President &CEO | Buy | 7,000 | $14.85 | $103,950.00 | +20.2% | |
| Mar 1, 2016 | Omenn Gilbert S | Director | Buy | 5,000 | $15.28 | $76,400.00 | +100.0% | |
| Jan 27, 2016 | Mayleben Timothy M | President &CEO | Buy | 3,600 | $15.88 | $57,168.00 | +11.6% | |
| Jan 15, 2016 | Mayleben Timothy M | President &CEO | Buy | 7,200 | $14.08 | $101,376.00 | +30.2% | |
| Apr 24, 2015 | Goldstein Dov A Md | Director | Sell | 217,469 | $108.22 | $23,534,372.60 | -3.7% | |
| Apr 24, 2015 | Aisling Capital II LP | 10% Owner | Sell | 217,469 | $108.22 | $23,534,372.60 | -3.7% | |
| Mar 19, 2015 | Enright Patrick G74 | Director | Sell | 500,000 | $111.66 | $55,831,597.19 | -8.9% |